Celgene’s Revlimid scores first-of-its-kind myeloma indication in EU
January 27, 2017Sales and Marketing Celgene, Revlimid, multiple myeloma
Celgene’s Revlimid (lenalidomide) has become the first licensed monotherapy treatment for newly diagnosed multiple myeloma in patients who have undergone …
Google’s life sciences business gains $800 million funding in pivot to Asia
January 27, 2017Medical Communications, Sales and Marketing China, Temasek, Verily, google
Verily, a life sciences company owned by Alphabet, Google’s umbrella company, has announced that it has received $800 million in …
Five most talked about mergers and acquisitions of 2016
January 27, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Actavis, Bayer, Boehringer, Johnson & Johnson, Sanofi, Teva, acquisition, mergers, monsanto, pharma
2017 has kicked off with a bang – as Johnson & Johnson confirmed a $30 billion deal to takeover of …
Top Ten most popular articles on Pharmafile.com this week
January 27, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing biggest news, biggest stories, top 10, top 10 stories, top stories, top ten
We’re nearing the end of the first month of the year and acqusitions have begun to introduce themselves with bang, …
Innovative routes to market: Rethinking the life sciences distribution model
January 27, 2017Manufacturing and Production, Medical Communications, Sales and Marketing Deloitte, distribution
Originally published in the latest issue of Pharmafile, Deloitte’s life sciences director Lee Feander discusses the often-undervalued importance of distribution …
Celgene to acquire Delinia in a potential $775 million deal
January 27, 2017Medical Communications Celgene, Delinia
Celgene has shelled out $300 million upfront, with a potential further $475 million in milestone payments, for Delinia, an autoimmune …
Skin cancer-detecting AI “on par with board-certified dermatologists”
January 27, 2017Medical Communications, Research and Development AI, Cancer, skin cancer
New research has found that artificial intelligence repurposed by researchers at Stanford University to identify skin cancer in images has …
Teva agrees $225 million fee in antitrust case
January 27, 2017Medical Communications Barr Laboratories, Teva, fine
Barr Laboratories, a subsidiary of Teva Pharmaceuticals, has settled an antitrust class action for $225 million. The case relates to …
New CFO for Diurnal
January 26, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Richard Bungay has been named as the new chief financial officer (CFO) of Diurnal; he has succeeded former CFO Ian …
NICE approves Imbruvica for second-line leukaemia treatment
January 26, 2017Medical Communications, Sales and Marketing AbbVie, CLL, Janssen, ibrutinib, imbruvica
NICE has issued its Technology Appraisal Guidance (TAG) that has recommend Imbruvica (ibrutinib) for the treatment of chronic lymphocytic leukaemia …
Two infants in remission from leukaemia after CAR T-Cell therapy
January 26, 2017Research and Development
Researchers at the Great Ormond Street Hospital have published the successful treatment of two infants suffering from leukaemia by treatment …
India’s NPPA slashes essential drug prices by up to 50%
January 26, 2017Sales and Marketing India, nppa, pricing
India’s governmental regulatory agency, the National Pharmaceutical Pricing Authority (NPPA), has addressed the pricing of 33 medicines including antibiotics and …
Jazz Pharmaceuticals UK supplier hit with FDA warning
January 26, 2017Manufacturing and Production Erwinaze, Porton Biopharma, jazz pharmaceuticals
UK-based Porton Biopharma, supplier of Irish company Jazz Pharmaceuticals’ leukaemia treatment Erwinaze, has been slapped with an FDA warning letter …
J&J finally seals $30 billion deal for Actelion
January 26, 2017Sales and Marketing Actelion, Janssen, Johnson & Johnson
Johnson & Johnson has, as expected, wrapped up the deal to acquire Actelion in a deal worth $30 billion, working …
Regeneron agrees ownership of HQ for $720m after 25 years
January 25, 2017Manufacturing and Production, Medical Communications Regeneron
After leasing the property for 25 years, Regeneron has agreed to take ownership of its headquarters and buy the Landmark …
Hospira in US-wide recall of product due to contamination
January 25, 2017Medical Communications Contamination, Hospira, Pfizer
Hospira, a company owned by Pfizer, has been forced to recall a batch of injectable drugs due to “the presence …
Takeda UK names new market access director
January 25, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Takeda
Takeda UK has appointed Peter Wheatley Price to the role of market access director, where he will also sit on …
MHRA accepts Roche’s Tecentriq into Early Access to Medicines scheme
January 25, 2017Research and Development, Sales and Marketing MHRA, Roche, eams, tecentriq
Roche’s Tecentriq (atezolizumab) has scored another positive opinion, this time from the Medicines and Healthcare products Regulatory Agency (MHRA), which …
Statins revealed to potentially aid cancer treatment
January 25, 2017Research and Development Cancer, University of Kansan, statins
New research, conducted at the University of Kansas, has emerged that reveal a potential use for statins beyond their current …
Two-step treatment cuts off cancer’s backup defences
January 25, 2017Research and Development Cancer, sarcoma, washington university
New research conducted at Washington University’s School of Medicine and published in Cell Reports details a new method for fighting …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
